Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Meltem CaglarMurat TuncelEgemen YildizErdem KarabulutPublished in: Annals of nuclear medicine (2020)
Ga-PSMA is superior to BS for the evaluation of metastatic disease in patients with PCa. However, BS can also detect bone metastases in patients with PCa with a minimum sensitivity of 75%. Biochemical data are helpful to select patients with a high pretest probability who should undergo BS first as a part of the initial workup from an economic point of view. Due to its higher cost, Ga-PSMA PET should be performed in a selective group of patients when BS results are inconclusive or metastasis-directed therapy is planned.
Keyphrases
- pet ct
- prostate cancer
- positron emission tomography
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- small cell lung cancer
- peritoneal dialysis
- radical prostatectomy
- prognostic factors
- computed tomography
- stem cells
- mesenchymal stem cells
- machine learning
- loop mediated isothermal amplification
- soft tissue
- pet imaging
- quantum dots
- postmenopausal women
- bone marrow